At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIAF bioAffinity Technologies, Inc.
Market Closed 10-09 16:00:00 EDT
4.73
-0.91
-16.22%
盘后4.72
+0.00-0.11%
19:57 EDT
High5.48Low4.68Vol657.43K
Open5.41D1 Closing5.64Amplitude14.19%
Mkt Cap6.06MTradable Cap6.03MTotal Shares1.28M
T/O3.30MT/O Rate51.54%Tradable Shares1.28M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Wallachbeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-the-Market Under NASDAQ Rules
THOMSON REUTERS  ·  10-10 00:30
Wallachbeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-the-Market Under NASDAQ Rules
BioAffinity Technologies Prices $4 Million Registered Direct Offering
MT Newswires Live  ·  10-09 00:52
BioAffinity Technologies Prices $4 Million Registered Direct Offering
bioAffinity Technologies Inc trading halted, volatility trading pause
TIPRANKS  ·  10-09 00:10
bioAffinity Technologies Inc trading halted, volatility trading pause
BioAffinity Technologies announces $4M registered direct offering
TIPRANKS  ·  10-09 00:10
BioAffinity Technologies announces $4M registered direct offering
bioAffinity Sells Warrants in Private Placement for up to 980,072 Shares
Reuters  ·  10-09 00:07
bioAffinity Sells Warrants in Private Placement for up to 980,072 Shares
NASDAQ Trade Halt Volatility Trading Pause at 12:07 Pm
Reuters  ·  10-09 00:07
NASDAQ Trade Halt Volatility Trading Pause at 12:07 Pm
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-the-Market Under NASDAQ Rules
THOMSON REUTERS  ·  10-09 00:07
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-the-Market Under NASDAQ Rules
bioAffinity Technologies Wins Japan Patent Allowance for CyPath Lung AI Algorithm
Reuters  ·  10-08 20:02
bioAffinity Technologies Wins Japan Patent Allowance for CyPath Lung AI Algorithm
BioAffinity reports over 100% growth in CyPath Lung sales through Q3
TIPRANKS  ·  10-06
BioAffinity reports over 100% growth in CyPath Lung sales through Q3
bioAffinity Says CyPath Lung Test Sales More than Double Through Q3 2026
Reuters  ·  10-06
bioAffinity Says CyPath Lung Test Sales More than Double Through Q3 2026
bioAffinity Technologies Partners with AvMEDICAL to Distribute CyPath Lung Test Across Federal Healthcare Market
Reuters  ·  09-30
bioAffinity Technologies Partners with AvMEDICAL to Distribute CyPath Lung Test Across Federal Healthcare Market
BioAffinity to present clinical, veteran-focused data on CyPath Lung
TIPRANKS  ·  09-22
BioAffinity to present clinical, veteran-focused data on CyPath Lung
bioAffinity Launches 2,000-Patient FlowPath Lung Study Testing CyPath Lung in Veteran, Military Populations
Reuters  ·  09-22
bioAffinity Launches 2,000-Patient FlowPath Lung Study Testing CyPath Lung in Veteran, Military Populations
Top Midday Gainers
MT Newswires Live  ·  09-18
Top Midday Gainers
bioAffinity Technologies Inc trading halted, volatility trading pause
TIPRANKS  ·  09-18
bioAffinity Technologies Inc trading halted, volatility trading pause
BioAffinity Technologies announces grant of Hong Kong patent for CyPath Lung
TIPRANKS  ·  09-17
BioAffinity Technologies announces grant of Hong Kong patent for CyPath Lung
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's Cypath® Lung Noninvasive Lung Cancer Diagnostic
THOMSON REUTERS  ·  09-17
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's Cypath® Lung Noninvasive Lung Cancer Diagnostic
bioAffinity Technologies - Cypath Lung Receives Dual Patent Protection in Hong Kong and China
THOMSON REUTERS  ·  09-17
bioAffinity Technologies - Cypath Lung Receives Dual Patent Protection in Hong Kong and China
BioAffinity Technologies regains compliance with Nasdaq listing requirements
TIPRANKS  ·  09-09
BioAffinity Technologies regains compliance with Nasdaq listing requirements
bioAffinity Technologies Regains Compliance with NASDAQ Listing Requirements
THOMSON REUTERS  ·  09-09
bioAffinity Technologies Regains Compliance with NASDAQ Listing Requirements

Introduction

Company Name.
bioAffinity Technologies, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
Issue price:
--